Human Pharmaceuticals segment
Eli Lilly & Co.’s (LLY) Human Pharmaceuticals business reported revenues of ~$5.6 billion during the second quarter. This represents 10.0% YoY (year-over-year) revenue growth, compared to the second quarter of 2017.
This revenue growth was driven by a 9.0% increase in volume and a 2.0% positive impact of foreign exchange, partially offset by a marginal decrease due to prices. The chart below compares the revenues of the endocrine franchise’s key products since the first quarter of 2017.
Eli Lilly’s (LLY) endocrine products portfolio includes Humalog, Humulin, Basaglar, Trulicity, Jardiance, Trajenta, and Forteo. During the second quarter, Humalog, Basaglar, Jardiance, and Trulicity reported revenue growth. However, sales of Humulin and Forteo declined, and Trajenta reported nearly flat revenues during the quarter. The company’s endocrine products also include Glucagon, Humatrope, Actos, and Humapen.
Humalog products, which are mealtime insulin products, reported 13.0% YoY revenue growth to $769.8 million during the second quarter, compared to ~$678.4 million during the second quarter of 2017. This revenue increase was driven by 19.0% growth in its US sales to $464.5 million due to higher realized prices. This increase was also due to 6.0% growth in international sales to $305.2 million during the second quarter.
Humulin products, which are concentrated insulin products, reported revenues of $346.0 million during the second quarter. This represents a 3.0% decrease in YoY revenues compared to the second quarter of 2017. This decline was driven by an 18.0% decrease in international sales and partially offset by a 5.0% increase in its US sales during the quarter.
Forteo, an osteoporosis drug, reported revenues of ~$434.5 million during the second quarter. This represents a 3.0% YoY revenue decrease, compared to ~$446.7 million during the second quarter of 2017. The decline in Forteo’s revenues was driven by a 10.0% decrease in its US sales, which was partially offset by 7.0% growth in its international sales during the quarter.
Later in this series, we’ll discuss the performance of Basaglar, Jardiance, Trulicity, and other new drugs in Eli Lilly’s portfolio.